2009
DOI: 10.1165/2009-0122r
|View full text |Cite
|
Sign up to set email alerts
|

Macrophage Chitinase 1 Stratifies Chronic Obstructive Lung Disease

Abstract: Diagnosis and therapy of chronic inflammatory lung disease is limited by the need for individualized biomarkers that provide insight into pathogenesis. Herein we show that mouse models of chronic obstructive lung disease exhibit an increase in lung chitinase production but cannot predict which chitinase family member may be equivalently increased in humans with corresponding lung disease. Moreover, we demonstrate that lung macrophage production of chitinase 1 is selectively increased in a subset of subjects wi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

6
53
4

Year Published

2012
2012
2020
2020

Publication Types

Select...
7
1

Relationship

4
4

Authors

Journals

citations
Cited by 50 publications
(63 citation statements)
references
References 22 publications
6
53
4
Order By: Relevance
“…Thus, our data suggested the hypothesis that changes in the activation level of PNECs or the responsiveness of other airway cell types to stimulation by PNEC contents could contribute to olfactory hypersensitivity in airway disease. We therefore determined the levels of PNECs in lung tissues obtained from lung transplant recipients with severe COPD versus corresponding tissues from lung transplant donors without COPD (42,43). In agreement with our hypothesis, we found increased numbers of OR2W1-and proprotein convertase subtilisin/kexin type 2-expressing PNECs in lung tissues from subjects with COPD relative to control subjects without COPD, without any detectable differences in PNEC morphology ( Figures 5A-5C).…”
Section: Resultssupporting
confidence: 82%
“…Thus, our data suggested the hypothesis that changes in the activation level of PNECs or the responsiveness of other airway cell types to stimulation by PNEC contents could contribute to olfactory hypersensitivity in airway disease. We therefore determined the levels of PNECs in lung tissues obtained from lung transplant recipients with severe COPD versus corresponding tissues from lung transplant donors without COPD (42,43). In agreement with our hypothesis, we found increased numbers of OR2W1-and proprotein convertase subtilisin/kexin type 2-expressing PNECs in lung tissues from subjects with COPD relative to control subjects without COPD, without any detectable differences in PNEC morphology ( Figures 5A-5C).…”
Section: Resultssupporting
confidence: 82%
“…In this case, we again found no difference in acute illness in Il33 Gt/Gt versus WT mice (Figure 4, A-C), but observed significant blockade of the expected development of chronic disease, signified by IL-13 and mucus production and M2 differentiation (Figure 4, D-F). Together with our previous work (11,12), these 3 approaches (anti-IL1RL1 mAb, IL1RL1 deficiency, and IL-33 deficiency) served to demonstrate a specific role for IL-33/IL-33 receptor signaling in driving lung IL-13 and mucus production in the postviral mouse model of chronic obstructive lung disease.…”
Section: Resultsmentioning
confidence: 86%
“…Analysis of this model uncovered an innate immune axis involving semi-invariant NKT cells and alternatively activated (M2) macrophages that resulted in IL-13 expression and consequent airway hyperreactivity (monitored by methacholine-induced bronchoconstriction) and mucus overproduction (signified by mucin MUC5AC expression) (11). We also found initial evidence of IL-13 expression along with M2 monocyte/macrophage accumulation and MUC5AC production in the lungs of patients with severe COPD (11)(12)(13). These results identified an innate immune response to translate viral infection into chronic obstructive lung disease, but still did not explain how the response could be perpetuated.…”
Section: Introductionmentioning
confidence: 72%
“…A proof-of-concept analysis of a small number of these patients provided preliminary evidence of increased numbers of iNKT cells and IL-13-positive macrophages in the lung in concert with mucus overproduction (109). Subsequent analysis defined chitinase 1 as a relatively selective marker of M2 macrophage activation and found increased chitinase 1 levels in lung as well as peripheral blood samples in a larger group of COPD patients (112). Here again, the M2 macrophage abnormality was most prominent in those with severe disease.…”
Section: Innate Immune Cells and Viral Diseasementioning
confidence: 97%
“…Particular challenges for the goal of innate immune blockade include the built-in redundancy of the innate response, the capacity to do harm as well as good when this response is unbalanced, and the requirement for noninvasive clinical biomarkers and imaging approaches to stratify as well as monitor this response in vivo in patients. Initial application of clinical biomarkers for innate immune responses suggests that only a subset of asthma or COPD patients is likely to manifest any given molecular target as a component of their disease (112,118). The application of high-fidelity experimental models in conjunction with validation in these models and in humans will be required to develop new therapeutics and corresponding clinical biomarkers that target the proper subset in asthma or other common inflammatory diseases.…”
Section: Improving Innate Immunity For Prevention and Curementioning
confidence: 99%